PI 166
Alternative Names: PI-166Latest Information Update: 04 Nov 2017
At a glance
- Originator University of New South Wales
- Developer Progen Pharmaceuticals Limited; TBG Diagnostics Limited
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Liver cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Australia
- 22 Jul 2008 Discontinued - Phase-I for Liver cancer in Australia (IV)
- 25 Jun 2007 Progen Pharmaceuticals raises $A34.1 million in Entitlements Offer